Paris Cedex 14

• RIISC Recruiting
  2024-513669-38-00 5 2023-05-17 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
• First-in-human study of OT-A201 in patients with selected hematological malignancies and solid tumors Recruiting
  2024-511936-28-00 1 2023-05-12 Relapsed/refractory hematological malignancies or advanced/metastatic
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting
  2024-511884-27-00 3 2022-11-09 CD205+ve recurrent and/or metastatic tumor types including but not lim
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 Unresectable head and neck squamous cell carcinoma, metastatic head an
• Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease: multicentric randomized phase … Recruiting
  2024-511868-83-00 5 2021-02-05 Antisynthetase syndrome-related interstitial lung disease
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blin … Recruiting
  2024-515276-12-00 5 2020-07-01 Postpartum Hemorrhage
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting
  2024-512173-27-00 5 2019-03-21 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment wi
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre … Ended recruitment
  2022-502103-30-00 4 2023-04-25 advanced non-squamous non-small cell lung cancer
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M … Ended recruitment
  2024-510837-16-00 4 2022-12-13 locally-advanced and unresectable or metastatic NSCLC with KRAS G12C
• The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment
  2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti

Showing 25–48 of 71 trials